Tag - OPXA

By Len Zehr With its Phase 2b clinical trial in secondary-progressive multiple sclerosis (SPMS) running nicely, Opexa Therapeutics (NASDAQ:OPXA) is considering adding a new disease indication to its antigen-specific T...